The WHO voices concerns about a proposed trial for the hepatitis B birth dose vaccine in Guinea-Bissau, citing ethical and scientific issues.
The World Health Organization (WHO) has reaffirmed the critical role of the hepatitis B birth dose vaccine as a public health intervention, highlighting its effectiveness and the proven benefits it offers in preventing life-threatening liver diseases. This vaccine has been in use for over thirty years and is included in the national immunization schedules of more than 115 countries. Timely administration of this birth dose not only protects individual newborns but is also vital for national and global initiatives geared towards eliminating hepatitis B.
In light of recent media inquiries, the WHO has issued a statement regarding a proposed randomized controlled trial (RCT) on the hepatitis B birth dose vaccine planned in Guinea-Bissau. The organization has expressed significant concerns pertaining to the scientific rationale, ethical protections for study participants, and alignment with foundational principles governing research on human subjects.
Ethics of Withholding a Proven Vaccine The WHO articulates that withholding the hepatitis B vaccine—proven to prevent 70% to 95% of mother-to-child transmission—poses an ethical dilemma. By allowing some newborns to be without this life-saving intervention, they may be exposed to severe and potentially irreversible health outcomes, including chronic hepatitis B infection, cirrhosis, and liver cancer. This highlights the ethical responsibility of researchers to ensure participant safety.
Lack of Justification for a No-Treatment Group WHO maintains that the inclusion of a placebo or no-treatment group in vaccine trials is generally only justifiable when there is no effective intervention available or when such a design is essential to answer questions of efficacy or safety. Publicly available details suggest that the planned study does not meet these criteria, which raises doubts about its scientific justification.
Concerns Over Study Design The organization has criticized the trial's design, labeling it as biased and of limited utility. The single-blind, no-treatment-supported framework poses a considerable risk for bias, which may significantly affect the study's outcomes and their relevance for policy decisions. WHO urges that research must adhere to high scientific and ethical standards to ensure meaningful and applicable results.
Ethical Implications of Resource Scarcity Furthermore, WHO emphasizes that resource challenges cannot serve as a rationale for withholding necessary care in research settings. Ethical standards demand that risks to participants are minimized, and tangible benefits are secured. The current protocol, as outlined publicly, appears deficient in ensuring even a base level of harm reduction for participants, including failing to prioritize screening for hepatitis B among pregnant women and providing adequate vaccination for newborns at risk.
Currently, Guinea-Bissau has paused the planned study while conducting further technical evaluations. In this context, the WHO expresses its readiness to assist Guinea-Bissau in contemplating future actions aimed at accelerating the implementation of the hepatitis B birth dose vaccine. The organization advocates for several initiatives, including:
The WHO remains committed to collaborating with national authorities, researchers, and various stakeholders to guarantee that all newborns in Guinea-Bissau and worldwide receive the timely and evidence-supported protection that the hepatitis B birth dose vaccine offers. The organization stresses the importance of ensuring that any research conducted in this area adheres to the highest ethical and scientific benchmarks.
Conclusion and Context Hepatitis B is responsible for hundreds of thousands of deaths globally each year, with transmission during childbirth being the most prevalent route for long-term infection. Approximately 90% of infants who contract the virus during birth are likely to develop chronic infections, leading to high risks of cirrhosis and liver cancer later in life. In Guinea-Bissau, it is estimated that more than 12% of adults are living with chronic hepatitis B as of 2022, and about 2% of children under five showed infection in 2020, figures that significantly exceed the global target of less than 0.1% for this age group.
Recognizing these figures, Guinea-Bissau's government formally resolved to incorporate the hepatitis B birth dose into its national immunization strategy in 2024, with the rollout scheduled for 2028. This official decision not only validates the vaccine's importance but also reinforces the ethical imperative to ensure that all newborns receive appropriate protection against hepatitis B.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.